Day One Biopharmaceuticals Inc (DAWN)
Official siteBIOTECHNOLOGY
Last updated: Apr 23, 2026 at 5:00 PM ET
Earnings
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 18.2% above its 50-day moving average, and the 50-day average is above the 200-day average. The 14-day RSI is 80.3, above 70, the overbought line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about DAWN
News
No news available
Company news will appear here when available
Day One Biopharmaceuticals Competitors
Peers by sector and size for Day One Biopharmaceuticals (DAWN) include Palvella Therapeutics, Schrodinger and Perrigo Company.
Sector: Healthcare
DAWN Earnings: Beat Rate
- Beat rate
- 5 of 8 quarters (62.5%)
- Average surprise
- 41.0%
DAWN Earnings Call
The latest DAWN earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptDAWN ETF Holders
GNG tracks 4 ETFs that hold DAWN. The largest weights:
- iShares Russell 2000 ETF (IWM), 0.02% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.02% of the fund
- Vanguard Extended Market Index Fund ETF Shares (VXF), 0.02% of the fund
- Schwab U.S. Broad Market ETF (SCHB), <0.01% of the fund
Updated Feb 26, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About DAWN
Does DAWN pay dividends?
Day One Biopharmaceuticals Inc (DAWN) does not currently pay a regular dividend.
DAWN pages: Overview, Financials
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.